The COPPER Trial: Comparision of a tumour marker in patients with appendix or right sided colon cancer

Not Applicable

Recruiting

• Conditions: Appendiceal cancer; Colon cancer; Cancer - Bowel - Back passage (rectum) or large bowel (colon); Cancer - Other cancer types; Blood - Other blood disorders

• Registration Number: ACTRN12623000413628
• Lead Sponsor: Professor David Morris

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-26
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

*Sex: All
*Age range: 18 years and above
*Disease status: Appendiceal or right sided colon cancer (suspected or confirmed)
*Willingness to give written informed consent and willingness to participate to and comply with the study.
* Pre-operative carcino-embryonic antigen (CEA) level > 5 microg/

Exclusion Criteria

*Participants who cannot provide informed consent.
*Patients who have had a previous peritonectomy (including those who have previously undergone a right hemicolectomy).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Carcinoembryonic antigen (CEA) levels determined from the portal vein[ Blood samples to be collected during surgery];Carcinoembryonic antigen (CEA) levels determined from the peripheral vein[ Blood samples to be collected during surgery];Albumin levels determined from the peripheral and portal vein as a composite primary outcome for correlation..[ Blood samples to be collected during surgery]

Secondary Outcome Measures

Name	Time	Method
Immunohistochemical and histopathological (i.e., differentiation, node metastasis, lymphovascular invasion, etc) variables of the primary appendiceal and right sided colon cancer by NSW Health pathology as part of routine histopathological reporting - Composite secondary outcomes[ Tumour samples to be collected during surgery<br>Outcomes measured throughout hospital stay and during outpatient follow-up and surveillance, e.g., 6- and 12-monthly post-surgery follow-up then yearly for 5 years]